• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

    105.78 +3.00 (+2.92%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Rhythm Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Q2 Earnings Call Highlights ↗
    Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call ↗
    Rhythm Pharmaceuticals (NASDAQ:RYTM) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to... 
    Via Benzinga
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    My Top 3 Stocks to Buy in May ↗
    Forget "sell in May and go away." These stocks are good picks to buy and hold. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗
    Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan. 
    Via Benzinga
    News headline image
    Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗
    Rhythm (RYTM) Q1 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗
    It released an encouraging quarterly earnings report and business update before market open. 
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
    Via MarketMinute
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Rhythm Pharmaceuticals Announces Changes to Board of Directors
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
    This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful? 
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.